Insights on Patent
473 total results. Page 11 of 19.
The United States Patent and Trademark Office greeted the new year with a welcome gift: “2019 Revised Patent Subject Matter Eligibility Guidance” that updates the framework on subject matter eligibility under 35 U.S.C. § 101.
As the government shutdown stretches on, pharmaceutical companies must manage the partial shutdown of the U.S. Food and Drug Administration (FDA).
Schiff Hardin successfully secured a favorable outcome for our client, Fresenius Kabi USA LLC, in a patent-infringement suit filed by Hospira Inc., which paves the way for Fresenius to market a new generic drug.
Joel Wallace was quoted on a recent ruling from Federal Judge Reed O’Connor in the Federal District Court in Fort Worth, Texas, that the Affordable Care Act’s (ACA) individual coverage mandate is unconstitutional and, in the absence of the individual mandate, the rest of the ACA cannot stand.
Arent Fox has successfully procured a patent for Acronis, a leading provider of cloud backup and cyber protection, for a new technology of verifying data integrity using a blockchain network.
In the quick pound of a gavel, the entire U.S. pharmaceutical and biologics industries were thrown into doubt after Judge Reed O’Connor of the United States District Court for the Northern District of Texas found the individual mandate of the Affordable Care Act (ACA) – and therefore the entire act – unconstitutional.
Intellectual Property Practice Group Co-Leader Imron Aly was quoted on how including patents in the U.S. Food and Drug Administration’s “Purple Book” — which lists biological products, including any biosimilar and interchangeable biological products — might affect developers.
Bitcoin cryptocurrency and other cryptocurrencies have experienced immense growth, as demonstrated by the skyrocketing values and development of technical solutions involving blockchain technologies.
Intellectual Property Practice Group Co-Leader Imron Aly described the three key features of the U.S. Food and Drug Administration’s Biosimilar Action Plan: education, interchangeability, and international data sharing.
Today’s oral arguments in Supreme Court case Helsinn Healthcare v. Teva illustrate the power that a successful appeal could have to change a longstanding doctrine and significantly impact how businesses handle intellectual property transactions.
Hatch-Waxman and Biosimilars Practice Group Leader Imron Aly was quoted on why patients in the United States may have to wait longer than those in the European Union for the biosimilar adalimumab, referencing the brand name drug, Humira.
Starting on January 1, 2020, automotive dealers will need to comply with the strongest online privacy law in the United States, the California Consumer Privacy Act of 2018.
Intellectual Property Practice Group Co-Leader Imron Aly spoke with The Center for Biosimilars on key takeaways from the long-running case Saint Regis Mohawk Tribe, Allergan v. Mylan
WASHINGTON — Twenty-four Arent Fox LLP practices have been recognized in the 2019 “Best Law Firms” rankings that are published annually by US News & World Report and Best Lawyers.
On October 11, the United States Patent and Trademark Office published a new final rule altering the claim construction standard applied in inter partes review, post grant review, and covered business method review proceedings.
Imron Aly and Sailesh Patel have been named Life Sciences Stars in the Hatch-Waxman Patent Litigation Practice Area by LMG Life Sciences in its 2018 guide.
Intellectual Property Group Co-Leader Imron Aly represented Alkem Laboratories Ltd. as part of a group of generic drug makers urging a Federal Circuit panel to nix patents for the tapentadol opioid painkiller Nucynta, marketed by Depomed (now Assertio). IP Law360 reported on the oral argument.
On August 28, New York Partner and Chairperson of the USPTO’s Patent Public Advisory Committee, Marylee Jenkins, was quoted in Law360 regarding the week-long outage of the USPTO’s online patent filing system earlier in the month.
About nine months ago, the en banc Federal Circuit decided in Aqua Products v. Matal that the America Invents Act and related regulatory landscape place the burden in an inter partes review on the non-movant petitioner to disprove patentability of a patent owner’s proposed motion to amend.
Intellectual Property Practice Group Co-Leaders Imron Aly and Sailesh Patel were featured in Leading Lawyers Magazine—2018 Business Edition for their successful track record in challenging giant pharmaceutical companies to bring generic drugs to the marketplace.
In WesternGeco LLC v. ION Geophysical Corp., the Supreme Court recently held that patent holders can recover lost foreign profits for patent infringement under 35 U.S.C. § 271(f).